Key Takeaways
- FDA updates Amyvid label to guide Alzheimer disease (AD) therapy decisions: The revised label supports both visual and quantitative assessment of amyloid plaques for improved diagnostic accuracy and treatment selection.
- Amyvid PET imaging improves Alzheimer diagnosis: Clinical trial and real-world data show Amyvid’s effectiveness in identifying β-amyloid plaques, helping differentiate AD from other cognitive conditions.
- AD burden continues to grow: Over seven million Americans live with AD, with costs projected to reach $1 trillion by 2050—underscoring the need for early and accurate diagnosis.
The FDA has approved an updated label for Eli Lilly’s Amyvid (florbetapir F 18 injection), reinforcing its role in diagnosing Alzheimer disease (AD). The revision clarifies that Amyvid may be used to evaluate amyloid plaque levels in individuals with cognitive impairment, including those being considered for amyloid-targeting therapies. Amyvid is a radiopharmaceutical used with PET imaging to estimate brain amyloid burden.1
How Does the Updated Amyvid Label Support Alzheimer’s Diagnosis and Treatment?
“Nearly 80% of Americans would prefer to know if they have an Alzheimer’s diagnosis before their memory and thinking symptoms disrupt daily life3, highlighting the importance of advanced diagnostic tools like amyloid PET and blood biomarker testing,” said Mark Mintun, MD, group VP, neuroscience research & development, Lilly, in a press release.
Expanded Use for Amyloid PET Imaging in Clinical Evaluation
The label now supports both visual and quantitative assessment of amyloid plaques. It also notes that amyloid PET imaging has been used in clinical trials to track changes in plaque burden as part of amyloid-targeting therapy evaluation. In patients not previously treated with such therapies, a negative scan suggests little or no plaque buildup, making AD less likely. A positive scan reflects moderate to frequent plaque presence, more consistent with an AD diagnosis.1
Safety Profile and Clinical Study Validation
Common adverse events associated with Amyvid include headache, muscle or joint pain, higher blood pressure, nausea, tiredness, and injection site reactions.2
According to a 2012 study published in the New England Journal of Medicine, Amyvid PET imaging improved the diagnosis of cognitive impairment by enabling detection of β-amyloid neuritic plaques. The study findings helped clarify how scan results can inform diagnostic decisions, in which sparse or no plaques lower the likelihood of AD, and moderate to frequent plaque levels increase diagnostic confidence or point to related conditions.
